% | $
Quotes you view appear here for quick access.

Sucampo Pharmaceuticals, Inc. Message Board

  • jrus2010 jrus2010 Aug 8, 2012 9:37 AM Flag

    SCMP moving towards profitability

    Was on the call last night, pretty surprised at the potential here.

    Net loss of only $800K for the quarter. Revs increasing from $14.4M in Q112 to $16.7M in Q212. They are on a run rate of about $64M in revs, which at a 5X multiple for companies with increasing revs, should put them at $320M market cap. They are currently trading at $171M market cap. They also have $88.6M in cash and equivalents at end of Q212.

    Major potential for PPS increase, as they have lots happening in Q3/Q412 including:
    -they just got Japan approval for Amitiza, and expect $15M milestone on first sale
    -potential UK approval for Amitiza by next month
    -FDA acceptance of their sNDA for non-cancer pain in Q3. This is the first oral product filed.
    -they just ironed out their differences with partner Takeda and fired the COO to smooth things over. I don't rule out a takeover at this point. They should be profitable in next 2 quarters.

    The issues with SCMP are a CEO who isn't the wall street type, and very little analyst coverage. This has bottomed out and will only go up from here.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
12.070.00(0.00%)Oct 27 4:00 PMEDT